The F.D.A. is expected to approve a new round of shots by Pfizer and Moderna as early as Monday to prepare Americans for the fall and winter season when infections usually tick upward.
Doing business in China, once seen as a can’t-miss opportunity, poses a troubling quandary: Reasons to stay can be as compelling as the reasons to retreat.